About

Our Company

RNACOREX is dedicated to llama biology and RNA engineering in service of biomedical research.

Our Mission

Making the llama immune repertoire accessible to research.

RNACOREX develops next-generation medical technologies at the intersection of animal immunization, VHH nanobodies and RNA production. Our conviction: the quality and traceability of starting biological material directly determine the success of the downstream nanobody discovery programs built on it.

The company runs its own R&D, as well as service and technology-transfer activities in the pharmaceutical and biotechnology fields, for academic and industrial partners.

At a Glance
HeadquartersAvanne-Aveney, France
ActivityBiotech R&D — animal immunization, VHH nanobodies, RNA
OversightDedicated scientific and veterinary team
ComplianceEU Directive 2010/63 on animal protection
Our Commitments

Three non-negotiable standards.

Animal welfare

Every immunization protocol is designed and monitored in line with the 3Rs principle and EU Directive 2010/63, with ethics committee review and continuous veterinary oversight.

Scientific rigor

Every RNA batch is qualified using standardized methods (Qubit, TapeStation) before release, with full traceability from sample collection to delivery.

Transparency

Our methods, quality thresholds and protocols are documented and shared with our partners, with no ambiguity about the origin of the material supplied.

Our Journey

RNACOREX's key milestones.

2024

R&D built out

Immunization, RNA extraction and quality control protocols are established, in compliance with EU Directive 2010/63.

2026

Naive RNA launch

Qualified naive llama RNA stocks become available immediately for research and development teams.

Contact

Need llama RNA or planning a VHH library project?

info@rnacorex.com
Send an email →